Carina Biotech news
Carina Biotech is extremely pleased to announce that it has raised $7.5 million at first close of its current funding round, welcoming on board new venture capital business Tenmile as the cornerstone investor together with strong support from existing investors.
“We are delig
Highlights
- Melbourne-based contract development and manufacturing organisation Cell Therapies will manufacture Carina Biotech’s LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer.
- Carina’s CAR-T cells are targeted at LGR5, a cancer stem cell marker that is highly expressed on colorectal cancer and other cancers.
- Colorectal (bowel) cancer is the deadliest cancer for Aus
Please Join Us
9:30 am – 5:00 pm
for Carina Biotech’s inaugural symposium
Carina has had five abstracts accepted for poster presentations at the AACR Annual Meeting which will take place from April 8 to April 13.
The poster presentations come after Carina’s recent submission of a pre-IND package to the FDA for Carina’s LGR5 CAR-T cell for the treatment of patients with advanced colorectal cancer.
Highlights
- Five conference abstracts will be presented as poster presentations at AACR in the immuno-onc
Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food & Drug Administration) for our CAR-T therapy that targets a cancer stem cell antigen known as LGR5.
This represents a major step towards taking our CAR-T cell (CNA3103) into a Phase I/IIa clinical trial in patients with advanced colorectal (bowel) cancer later this year.
Highlights
- A pre-IND